RailTel shares climbed 13.64 per cent to hit a high of Rs 323.25 apiece. The stock cut some gains and was later trading 13.01 ...

RailTel Corporation shares surged on Wednesday after the company secured multiple orders worth around Rs 608 crore, including ...

RailTel Corporation of India Ltd has received a Letter of Acceptance from Rail Vikas Nigam Limited for a ₹255.27 crore order ...

RailTel is doubling down on its infrastructure push after bagging a sizeable railway systems contract, reinforcing its role ...

Replimune has had its advanced melanoma treatment RP1 turned down by the FDA for a second time, a decision that has led the company to accuse the agency of inconsistencies in its review of the drug.

Replimune received a second FDA complete response letter for RP1 in advanced melanoma, raising questions about the viability of its oncolytic immunotherapy program. Replimune Group received a complete ...

Replimune disagrees with the FDA about whether the data set, upon which breakthrough therapy designation was awarded, is sufficient to allow this promising medicine to be made available to advanced ...

Replimune Group, Inc. stock drops after a second FDA rejection for RP1 melanoma; cash runway <12 months. Click for more on ...

There is a running joke in the construction industry: projects don’t get delayed; only completion dates move faster than time itself. Having sat through more th ...

Replimune Group submitted its first Biologics License Application for RP1 last year.

RailTel Corporation receives two LoAs from RVNL worth over ₹564 crore for SITC of integrated tunnel communication systems ...